Cost-effectiveness of detecting and treating diabetic retinopathy

Annals of Internal Medicine

Volumn 124, Issue 1 II, 1996, Pages 164-169

  Javitt, Jonathan C ^a   Aiello, Lloyd Paul ^b  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^b JOSLIN DIABETES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN;

COMPUTER MODEL; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; DIABETIC RETINOPATHY; HEALTH CARE COST; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OPHTHALMOSCOPY; PREVALENCE; PREVENTIVE HEALTH SERVICE; PRIORITY JOURNAL; SCREENING TEST; SYSTEM ANALYSIS;

EID: 0030034714     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-124-1_part_2-199601011-00017     Document Type: Conference Paper

References (55)

1. Klein HA, Moorehead HB. Statistics on blindness in the Model Reporting Area, 1969-1970 Bethesda, Maryland U S Department of Health, Education and Welfare, 1973 DHEW publication no 73-427 1970
2. National Society to Prevent Blindness, Operational Research Department. Vision Problems in the U.S . A Statistical Analysis New York National Society to Prevent Blindness, 1980 Available from. National Society to Prevent Blindness, 500 East Remington Road, Schaumburg, IL 60173
3. Klein R, Klein BE. Vision disorders in diabetes In: Diabetes in America. Diabetes Data Compiled 1984 Bethesda, Maryland: U.S. Department of Health and Human Services, 1985: ch 8.1-2. NIH publication no. 85-1468
4. The Diabetic Retinopathy Study Research Group. Photocoagulation treatment of proliferate diabetic retinopathy Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS report no. 8 Ophthalmology 1981; 88 583-600.
5. The Diabetic Retinopathy Study Research Group. Four risk factors for severe visual loss in diabetic retinopathy The third report from the Diabetic Retinopathy Study Arch Ophthalmol. 1979,97 654-5.
6. Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema Early Treatment Diabetic Retinopathy Study report number 1 Arch Ophthalmol 1985,103 1796-806
7. Early Treatment Diabetic Retinopathy Study Research Group. Early photocoagulation for diabetic retinopathy: ETDRS report no. 9 Ophthalmology 1991,98 766-85
8. Javitt JC, Aiello LP, Chiang Y, Ferris FL 3d, Canner JK, Greenfield S. Preventive eye care in people with diabetes is cost-saving to the federal government Implications for health-care reform Diabetes Care. 1994,17 909-17
9. Javitt JC, Aiello LP, Bassi LJ, Chiang YP, Canner JK. Detecting and treating retinopathy in patients with type 1 diabetes mellitus. Savings associated with improved implementation of current guidelines. Ophthalmology 1991;98:1565-74
10. Canner JK, Chiang YP, Javitt JC. PROPHET a Monte Carlo based simulation network model for a chronic progressive disease. The case of diabetic retinopathy. Proceedings of the Winter Simulation Conference 1992;25 1041-9
11. Dasbach EJ, Fryback DG, Newcomb PA, Klein R, Klein BE. Cost-effectiveness of strategies for detecting diabetic retinopathy. Med Care. 1991,29 20-39.
12. Public health focus. prevention of blindness associated with diabetic retinopathy MMWR Morb Mortal Wkly Rep. 1993,42:191-5.
13. Chiang YP, Bassi LJ, Javitt JC. Federal budgetary costs of blindness. Milbank Q. 1992;70:319-40
14. National Eye Health Education Program, Congressional Record, National Departments of Labor, Health and Human Services, Education, and related agencies, Appropriation Bill, 1988 Senate report 100-189 121
15. Ring A, Destefano F, Geiss L, et al. Centers for Disease Control community-based diabetes control program. In Davidson JK, ed. Clinical Diabetes Mellitus A Problem-oriented Approach New York. Thieme, Inc , 1991: 728-xxx
16. Diabetes 2000 Elimination of preventable blindness from diabetes by the year 2000 An educational program of the American Academy of Ophthalmology San Francisco The Academy; 1939 Available from. American Academy of Ophthalmology, P.O. Box 7424, San Francisco, CA 94120-7424.
17. Everhart J, Knowler WC, Bennet PH. Incidence and risk factors for noninsulin-dependent diabetes. In. National Diabetes Data Group, ed. Diabetes in America: Diabetes Data Compiled 1984 Bethesda, Maryland: U S Department of Health and Human Services, 1985 1-5 NIH publication no 85-1468.
18. Butler WJ, Ostrander LD Jr, Carman WJ, Lamphiear DE. Diabetes mellitus in Tecumseh, Michigan Prevalence, incidence, and associated conditions. Am J Epidemiol 1982,116 971-80
19. Melton LJ 3d, Palumbo PJ, Chu CP. Incidence of diabetes mellitus by clinical type. Diabetes Care 1983,6:75-86
20. Klein R, Klein BE, Moss SE. A population-based study of diabetic retinopathy in insulin-using patients diagnosed before 30 years of age Diabetes Care. 1985,8 (Suppl 1) 71-6
21. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin Epidemiologic Study of Diabetic Retinopathy II Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years Arch Ophthalmol 1984;102 520-6
22. Klein BE, Davis MD, Segal P, Long JA, Harris WA, Haug GA, et al. Diabetic retinopathy Assessment of severity and progression Ophthalmology 1984,91 10-7
23. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. IX Four-year incidence and progression of diabetic retinopathy when age at diagnosis is less than 30 years Arch Ophthalmol 1989;107:237-43
24. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. X Four-year incidence and progression of diabetic retinopathy when age at diagnosis is 30 years or more. Arch Ophthalmol. 1989;107:244-9
25. Ferris FL 3d. How effective are treatments for diabetic retinopathy? JAMA 1993,269 1290-1
26. Clinical Trials Branch, Office of Biometry, National Eye Institute, National Institutes of Health. Analysis of Early Treatment of Diabetic Retinopathy Study data Available from F L Ferns III, MD, National Institutes of Health, Building 31, Room 6A24, Bethesda, MD 20892
27. Blankenship GW. Fifteen-year argon laser and xenon photocoagulation results of Bascom Palmer Eye Institute's patients participating in the Diabetic Retinopathy Study Ophthalmology 1991;98:125-8
28. Vander JF, Duker JS, Benson WE, Brown GC, McNamara JA, Rosenstein RB. Long-term stability and visual outcome after favorable initial response of proliferate diabetic retinopathy to panretinal photocoagulation Ophthalmology 1991,98 1575-9
29. National Center for Health Statistics. Vital Statistics of the United States 1984 Life Tables (volume 2, section 6) Hyattsville, Maryland: Department of Health and Human Services; 1987.
30. Knatterud GL. Mortality experience in the diabetic retinopathy study Isr J Med Sci 1983,19 424-8.
31. Davis MD, Hiller R, Magli YL, Podgor MJ, Ederer F, Harris WA, et al. Prognosis for life in patients with diabetes relation to severity of retinopathy Trans Am Ophthalmol Soc 1979,77.144-70.
32. Klein R, Moss SE, Klein BE, DeMets DL. Relation of ocular and systemic factors to survival in diabetes Arch Intern Med 1989,149 266-72.
33. Dorman JS, Laporte RE, Kuller LH, Cruickshanks KJ, Orchard TJ, Wagener DK, et al. The Pittsburgh insulin dependent diabetes mellitus (IDDM) morbidity and mortality study Mortality results Diabetes. 1984, 33 271-6
34. American Academy of Ophthalmology Quality of Care Committee. Diabetic Retinopathy Preferred Practice Pattern San Francisco. The Academy, 1989 Available from American Academy of Ophthalmology, PO Box 7424, San Francisco, CA 94120-7424
35. Sussman EJ, Tsiaras WG, Soper KA. Diagnosis of diabetic eye disease JAMA 1982,247 3231-4
36. Moss SE, Klein R, Kessler SD, Richie KA. Comparison between ophthalmoscopy and fundus photography in determining severity of diabetic retinopathy Ophthalmology 1985,92:62-7
37. Doubilet P, Begg CB, Weinstein MC, Braun P, McNeil BJ. Probabilistic sensitivity analysis using Monte Carlo simulation A practical approach Med Decis Making. 1985;5 157-77.
38. Vital Statistics of the United States 1988. Washington, D C United States Department of Health and Human Services, Public Health Services, Centers for Disease Control, National Center for Health Statistics, 1988 vol 1, sect 4:17
39. Kenny SJ, Aubert RE, Geiss LS. Prevalence and incidence of non-insulin-dependent diabetes. In: National Diabetes Data Group, ed Diabetes in America Bethesda, Maryland. U S. Department of Health and Human Services, 1995 47-68 NIH publication no. 95-1468
40. Martin DB, Quint AR. Therapy for diabetes In National Diabetes Data Group, ed Diabetes in America Bethesda, Maryland: U S. Department of Health and Human Services, Public Health Service, 1985 XXIV.1 NIH publication no. 85-1468
41. U.S. Health Care Financing Administration. Average Medicare Allowable Charges for Specific Ophthalmic Procedures, 1990 Available from. Office of Statistics, Health Care Financing Administration, Room 1F2, Oak Meadows Building, 6325 Security Boulevard, Baltimore, MD 21207
42. Weinstein MC, Statson WB. Foundations of cost-effectiveness analysis for health and medical practices N Engl J Med 1977,296 716-21
43. Bradford DF. The choice of the discount rate for government investments. In Haveman RH, Margolis J, eds Public Expenditure and Policy Analysis 3d edition Boston. Houghton Mifflin, 1983 129-44.
44. Goldman L, Sia ST, Cook EF, Rutherford JD, Weinstein MC. Cost and effectiveness of routine therapy with long-term beta-adrenergic antagonists after acute myocardial infarction N Engl J Med 1988,319 152-7
45. Weinstein MC, Stason WB. Cost-effectiveness of interventions to prevent or treat coronary heart disease Annu Rev Public Health 1985;6:41-63
46. Discounting health care only a matter of timing? [Editorial] Lancet. 1992, 340 148-9
47. Parsonage M, Neuburger H. Discounting and health benefits Health Econ 1992,1 71-6
48. Johannesson M. On the discounting of gained life-years in cost-effectiveness analysis Int J Technol Assess Health Care. 1992,8:359-64
49. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin Epidemiologic Study of Diabetic Retinopathy VI. Retinal photocoagulation Ophthalmology 1987; 94:747-53
50. Witkin SR, Klein R. Ophthalmologic care for persons with diabetes. JAMA 1984,251 2534-7
51. Brechner RJ, Cowie CC, Howie LJ, Herman WH, Will JC, Harris MI. Ophthalmic examination among adults with diagnosed diabetes mellitus JAMA 1993,270 1714-8.
52. Singer DE, Nathan DM, Fogel HA, Schachat AP. Screening for diabetic retinopathy Ann Intern Med 1992,116 660-71
53. Drummond M. Consultant report to the National Eye Institute, 1987 Available from. National Eye Institute, Building 31, Room 6A-06, Bethesda, MD 20892
54. Detsky AS. Are clinical trials a cost-effective investment? JAMA 1989;262 1795-800
55. Laupacis A, Feeny D, Detsky AS, Tugwell PX. How attractive does a new technology have be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations Can Med Assoc J 1992; 146 473-81